Femquil
En vente sur le marché américain (selon le DSLD)
XYMOGEN, food supplement from the US market
Femquil (XYMOGEN), a food supplement au code-barres 871149001810, is described by its US market label. If sold in France, it would be subject to 5 points of French or European regulation, detailed below. Doses of folates are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine B6: up to 30 mg a day according to the label (at most 2 servings a day), above the maximum dose of 2 mg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- À vérifier
Vitamine B6: up to 30 mg a day according to the label, above the limite de sécurité from EFSAEuropean Food Safety Authority. for adults (12 mg a day). Le repère de l'EFSA porte sur l'apport total d'une journée, alimentation et compléments.
Source: EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), limite supérieure de sécurité (UL).
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/2340).
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Brassica oleracea L.: L'étiquetage doit comporter un avertissement recommandant aux personnes ayant une hypothyroïdie ou un traitement de la thyroïde de consulter leur médecin.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- XYMOGEN
- Barcode
- 871149001810
- Form
- Capsule
- One serving
- 2 capsules
- Servings
- up to 2 servings per day
- Other ingredients (in English, as written)
- Hypromellose, Water, Maltodextrin, Ascorbyl Palmitate, Microcrystalline Cellulose, Silica, L-Leucine, Tricalcium Phosphate, Hydroxypropyl Cellulose
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Vitamin B6 | Vitamin | 15 mg |
| Quatrefolic | Vitamin | 340 µg DFE (dietary folate equivalent) |
| Vitamin B12 | Vitamin | 200 µg |
| Calcium | Mineral | 60 mg |
| Magnesium | Mineral | 25 mg |
| Calcium D-Glucarate Tetrahydrate | Other substance | 100 mg |
| Diindolylmethane | Other substance | 50 mg |
| Green Tea Leaf Extract (Camellia sinensis) | Plant | 50 mg |
| Black Cohosh Rhizome, Root Extract (Actaea racemosa) | Plant | 50 mg |
| Chaste Tree Berry Extract | Plant | 50 mg |
| Turmeric Root Extract (Curcuma longa) | Plant | 25 mg |
| Rosemary Leaf Extract | Plant | 25 mg |
| Trans-Resveratrol | Other substance | 20 mg |
| Grape Seed Extract | Plant | 12.5 mg |
| TrueBroc (Brassica oleracea) | Plant | 4.5 mg |
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Femquil
Entered into DSLD on 23 August 2023. Retirée du marché américain le 8 September 2023 (selon le DSLD).- Same quantity, different name: Chaste Tree extract in this version; Chaste Tree Berry Extract on the displayed label (50 mg)
- Same quantity, different name: Folate in this version; Quatrefolic on the displayed label (340 mcg DFE)
- Same quantity, different name: Rosemary extract in this version; Rosemary Leaf Extract on the displayed label (25 mg)
- Same quantity, different name: Glucoraphanin in this version; TrueBroc on the displayed label (4.5 mg)
Official label: Femquil
Entered into DSLD on 21 November 2020. Retirée du marché américain le 18 August 2022 (selon le DSLD).- Active ingredient added : Black Cohosh extract (50 mg)
- Active ingredient added : Chaste Tree extract (50 mg)
- Active ingredient added : Folate (200 mcg DFE)
- Active ingredient added : Green Tea extract (50 mg)
- Active ingredient added : Rosemary extract (25 mg)
- Active ingredient added : Turmeric extract (25 mg)
- Active ingredient removed : Black Cohosh Rhizome, Root Extract (50 mg)
- Active ingredient removed : Chaste Tree Berry Extract (50 mg)
- Active ingredient removed : Green Tea Leaf Extract (50 mg)
- Active ingredient removed : Quatrefolic (340 mcg DFE)
- Active ingredient removed : Rosemary Leaf Extract (25 mg)
- Active ingredient removed : Turmeric Root Extract (25 mg)
- Same quantity, different name: Calcium D-Glucarate in this version; Calcium D-Glucarate Tetrahydrate on the displayed label (100 mg)
- Same quantity, different name: Glucoraphanin in this version; TrueBroc on the displayed label (4.5 mg)
Official label: Femquil
Entered into DSLD on 21 September 2018. Retirée du marché américain le 18 April 2019 (selon le DSLD).- Active ingredient added : 8-Prenylnaringenin (100 mcg)
- Active ingredient added : Black Cohosh extract (50 mg)
- Active ingredient added : Chaste Tree extract (50 mg)
- Active ingredient added : Folate (200 mcg DFE)
- Active ingredient added : Green Tea extract (50 mg)
- Active ingredient added : Rosemary extract (25 mg)
- Active ingredient added : Turmeric extract (25 mg)
- Active ingredient removed : Black Cohosh Rhizome, Root Extract (50 mg)
- Active ingredient removed : Chaste Tree Berry Extract (50 mg)
- Active ingredient removed : Green Tea Leaf Extract (50 mg)
- Active ingredient removed : Quatrefolic (340 mcg DFE)
- Active ingredient removed : Rosemary Leaf Extract (25 mg)
- Active ingredient removed : Turmeric Root Extract (25 mg)
- Same quantity, different name: Calcium D-Glucarate in this version; Calcium D-Glucarate Tetrahydrate on the displayed label (100 mg)
- Same quantity, different name: truebroc Glucoraphanin in this version; TrueBroc on the displayed label (4.5 mg)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Black Cohosh Rhizome, Root Extract
Read the warning, when it applies and the studies cited
Black Cohosh - Actaea Racemosa
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or develop symptoms of liver trouble (EMA 2018, 2007; Lynch et al. 2006; Mills et al. 2006; Cohen et al. 2004; NIH 2004).
6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you are pregnant (Brinker 2010; Hoffmann 2003; Tilgner 1999).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Turmeric Root Extract
Read the warning, when it applies and the studies cited
TURMERIC - CURCUMA LONGA - Oral
Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000)
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).
5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: All uses except for Source of antioxidants and Hepatoprotectant.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 26 September 2025
Turmeric -CURCUMA LONGA - Topical
Cautions and warnings
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Contraindications
Do not use on deep or puncture wounds, animal bites or serious burns.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : XYMOGEN
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.